NEXI-001
Phase 1b Expansion Study of Multi-Antigen Specific CD8+ T Cells After Decitabine-enhanced Lymphodepletion: an Adoptive Cellular Therapy for Patients with Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation from Matched HLA Donors
More Information
- Trial Status
- Not yet accepting
- Trial Phase
- Phase 1
- Enrollment
- 31 patients (estimated)
- Sponsors
- City of Hope Medical Center
- Collaborators
- National Cancer Institute (NCI)
- Tags
- Allogeneic Stem Cell Transplant, T Cell (Allogeneic), Post-Allogeneic Stem Cell Transplant
- Trial Type
- Treatment
- Last Update
- 4 days ago
- SparkCures ID
- 2007
- NCT Identifier
- NCT06572631
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.